Varicella Pneumonia Requires IV Acyclovir

Case highlights need for early intravenous antiviral treatment in adults with rash and hypoxia

By
Andrea Surnit
April 24, 2026
3 min

Conexiant

Overview

Varicella pneumonia in adults presents with fever, diffuse vesicular rash, hypoxia, and pulmonary infiltrates, requiring prompt intravenous acyclovir treatment. Early initiation of IV antiviral therapy within 24 hours of rash onset is linked to improved respiratory outcomes and reduced mortality.

Background

Varicella pneumonia is a serious complication of primary varicella infection, particularly in adults without prior immunity. It typically develops within the first week after rash onset and is characterized by respiratory symptoms and characteristic imaging findings. Mortality rates in hospitalized patients can be as high as 24%, especially among those requiring intensive care or mechanical ventilation. Early recognition and treatment are critical to improving patient outcomes.

Data Highlights

Parameter	Findings
Oxygen Saturation on Presentation	88% on room air
Laboratory Findings	Elevated C-reactive protein, leukopenia, elevated liver enzymes
Chest Imaging	Bilateral micronodules and ground-glass opacities, predominantly lower lobes
Imaging Prevalence in Adults with Primary Varicella	71% showed pneumonia findings
Mortality Rate in Hospitalized Patients	13.6% to 24%

Key Findings

Varicella pneumonia presents with generalized vesicular rash, fever, hypoxia, and pulmonary infiltrates.
Chest imaging typically shows bilateral micronodules and ground-glass opacities, especially in lower lobes.
Diagnosis is confirmed by PCR testing of vesicular fluid for varicella zoster virus.
Early intravenous acyclovir treatment within 24 hours of rash onset improves recovery and reduces respiratory failure and mortality risk.
Oral antiviral therapy may be used after clinical improvement; corticosteroids are not routinely recommended.
Varicella zoster immune globulin is reserved for postexposure prophylaxis, not treatment.

Clinical Implications

Clinicians should maintain a high index of suspicion for varicella pneumonia in adults presenting with compatible dermatologic and respiratory symptoms. Prompt initiation of intravenous acyclovir is essential, even before confirmatory testing results are available, to reduce morbidity and mortality. Supportive care remains important, and corticosteroids should generally be avoided.

Conclusion

Varicella pneumonia is a potentially life-threatening complication in adults without prior immunity, requiring early recognition and intravenous antiviral therapy. This approach leads to improved respiratory outcomes and decreased mortality.